In Q3 FY2026 (ended January 23, 2026), MiniMed Group reported revenue of $790 million, up 15.0% year-over-year. Net loss widened to $119 million from $10 million a year ago, and operating loss was $100 million versus a loss of $15 million. Diluted EPS was -$0.47, compared to -$0.04 in the prior year quarter.
•Revenue grew 15.0% YoY to $790 million.
•Net loss increased to $119 million from $10 million.
•Operating loss expanded to $100 million from $15 million.
•Diluted EPS was -$0.47, down from -$0.04.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Founded 1983Northridge, CaliforniaSubsidiary of Medtronic plc
MiniMed is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services.
The company serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services, as well as CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. Founded in 1983, MiniMed is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
MiniMed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices such as insulin pumps and pens, continuous glucose monitors, and other consumables, supplies, and related software and services. Its platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing, as well as Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections. Notable products include InPen, Simplera Sync, and Guardian 4 sensor, along with the CareLink software platform that provides support for people with diabetes, their caretakers, and healthcare professionals.
Where is MiniMed Group (MMED) listed and what currency is used?
MiniMed Group, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MMED. The company trades in U.S. dollars (USD), as it is headquartered in the United States. Being listed on a major U.S. exchange provides liquidity and visibility to investors, and the use of USD simplifies transactions for domestic and international investors alike.
What sector and industry does MiniMed Group (MMED) operate in?
MiniMed Group, Inc. operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This industry focuses on producing devices, instruments, and supplies used in medical procedures and patient care. As a medical technology company, MiniMed specializes in diabetes management equipment, including insulin pumps, continuous glucose monitors, and related consumables. The company's products are essential for people with type 1 diabetes (T1D) and a subset of those with type 2 diabetes (T2D) who require insulin therapy.
Where is MiniMed Group (MMED) headquartered and what markets does it serve?
MiniMed Group, Inc. is headquartered in Northridge, California, United States. The company serves people with diabetes who require insulin therapy, which includes all individuals with type 1 diabetes (T1D) and a subset of those with type 2 diabetes (T2D). While the headquarters is in the U.S., the company operates as a subsidiary of Medtronic plc, a global leader in medical technology. This relationship likely extends its reach to international markets, though specific geographic details are not provided in the available data.
How does MiniMed Group (MMED) make money?
MiniMed Group generates revenue by developing, manufacturing, and marketing medical equipment for diabetes management. Its product portfolio includes insulin delivery devices (pumps and pens), continuous glucose monitors, consumables, supplies, and related software and services. The company's platform includes Automated Insulin Delivery (AID) systems and Smart Multiple Daily Injection (MDI) systems, which generate recurring revenue from consumables like sensors and infusion sets. Additionally, the CareLink software platform provides data management and support services, potentially creating subscription or service-based revenue streams. As a subsidiary of Medtronic plc, MiniMed benefits from a larger distribution network and R&D capabilities.